Cardiol Therapeutics will participate in a fireside chat at the H.C. Wainwright global Investment conference on September 14, 2026. The live webcast will be available through the company’s investor events page, giving investors an online way to access the scheduled presentation while Cardiol advances its heart-disease therapy programs.

Key Highlights

  • Cardiol Therapeutics’ live fireside-chat webcast will be available through its Events & Presentations investor page.
  • CRD-38 is a subcutaneously administered formulation intended for inflammatory heart disease, including heart failure.
  • Cardiol Therapeutics will hold a Sept. 14 fireside chat at the Lotte New York Palace Hotel in New York.
  • A live webcast will be available through the Events & Presentations section of the company’s Investors webpage.

The event gives investors access to a live webcast through the company’s investor website as Cardiol (NASDAQ: CRDL) advances therapies for inflammatory and fibrotic heart disease.

The discussion will take place in New York at the Lotte New York Palace Hotel. Cardiol Therapeutics (NASDAQ: CRDL) will make the webcast available in the Events & Presentations section of its Investors webpage. The company identifies itself as a late-stage life sciences Business focused on anti-inflammatory and anti-fibrotic treatments for heart disease. CardiolRx, its lead small-molecule drug candidate, modulates inflammasome pathway activation. The FDA has granted CardiolRx Orphan Drug Designation for pericarditis, including recurrent pericarditis.

Pipeline Extends Into Heart Failure

The completed Phase II ARCHER study evaluated CardiolRx in acute myocarditis. Cardiol Therapeutics is also developing CRD-38, a subcutaneously administered formulation intended for inflammatory heart disease, including heart failure. The webcast will be accessible online through the company’s investor-events page.